Joan E. Herman
Known title: DirectorCIK: 0001248398
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Cathie Wood adds to Ionis position amid RNA sector interest. Cathie Wood has increased her holdings in Ionis Pharmaceuticals as part of a broader bet on two stocks. This move highlights continued investor interest in RNA therapeutics, a sector currently drawing attention for its innovation potential. While the stock is trading near its 52-week low, the average analyst target remains significantly higher than the current price.
Transaction History
| EHC | ▲ Buy | Grant | 85 | $0 | 7/15/2026 | View on chart |
| IONS | ▲ Buy | Option Exercise | 5,220 | $0 | 7/15/2026 | View on chart |
| EHC | ▲ Buy | Grant | 1,634 | $0 | 5/7/2026 | View on chart |
| EHC | ▲ Buy | Grant | 85 | $0 | 4/15/2026 | View on chart |
| EHC | ▲ Buy | Grant | 87 | $0 | 1/15/2026 | View on chart |
| IONS | ▲ Buy | Option Exercise | 12,000 | $481K | 11/19/2025 | View on chart |
| IONS | ▼ Sell | Open Market | 12,000 | $866K | 11/19/2025 | View on chart |
| IONS | ▲ Buy | Option Exercise | 32,000 | $2.0M | 11/19/2025 | View on chart |
| IONS | ▼ Sell | Open Market | 32,000 | $2.3M | 11/19/2025 | View on chart |
| EHC | ▲ Buy | Grant | 73 | $0 | 10/15/2025 | View on chart |
| EHC | ▲ Buy | Grant | 74 | $0 | 7/15/2025 | View on chart |
| IONS | ▲ Buy | Option Exercise | 4,079 | $0 | 7/15/2025 | View on chart |
| EHC | ▲ Buy | Grant | 1,424 | $0 | 5/1/2025 | View on chart |
| EHC | ▲ Buy | Grant | 76 | $0 | 4/15/2025 | View on chart |
| EHC | ▲ Buy | Grant | 83 | $0 | 1/15/2025 | View on chart |
| EHC | ▲ Buy | Grant | 81 | $0 | 10/15/2024 | View on chart |
| EHC | ▲ Buy | Grant | 80 | $0 | 7/15/2024 | View on chart |
| IONS | ▲ Buy | Option Exercise | 4,677 | $0 | 7/15/2024 | View on chart |
| EHC | ▲ Buy | Grant | 1,978 | $0 | 5/2/2024 | View on chart |
| EHC | ▲ Buy | Grant | 80 | $0 | 4/15/2024 | View on chart |
| EHC | ▲ Buy | Grant | 91 | $0 | 1/16/2024 | View on chart |
| EHC | ▲ Buy | Grant | 101 | $0 | 10/16/2023 | View on chart |
| EHC | ▲ Buy | Grant | 95 | $0 | 7/17/2023 | View on chart |
| IONS | ▲ Buy | Option Exercise | 5,333 | $0 | 7/17/2023 | View on chart |
| IONS | ▲ Buy | Option Exercise | 1,777 | $0 | 7/17/2023 | View on chart |
| IONS | ▲ Buy | Option Exercise | 3,555 | $0 | 6/12/2023 | View on chart |
| EHC | ▲ Buy | Grant | 2,385 | $0 | 5/4/2023 | View on chart |
| EHC | ▲ Buy | Grant | 99 | $0 | 4/17/2023 | View on chart |
| EHC | ▲ Buy | Grant | 99 | $0 | 1/17/2023 | View on chart |
| EHC | ▲ Buy | Grant | 123 | $0 | 10/17/2022 | View on chart |
| EHC | ▲ Buy | Grant | 226 | $0 | 7/20/2022 | View on chart |
| IONS | ▲ Buy | Option Exercise | 5,333 | $0 | 7/15/2022 | View on chart |
| IONS | ▲ Buy | Option Exercise | 1,777 | $0 | 7/15/2022 | View on chart |
| IONS | ▲ Buy | Option Exercise | 3,555 | $0 | 6/10/2022 | View on chart |
| EHC | ▲ Buy | Grant | 2,226 | $0 | 5/5/2022 | View on chart |
| EHC | ▲ Buy | Grant | 121 | $0 | 4/18/2022 | View on chart |
| EHC | ▲ Buy | Grant | 139 | $0 | 1/18/2022 | View on chart |
| EHC | ▲ Buy | Grant | 126 | $0 | 10/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Encompass Health Sets Q3 2026 Earnings Call Date
Encompass Health announced the date for its 2026 third-quarter earnings call. Recent coverage also highlights the company's small-format expansion strategy and potential undervaluation as it builds out its rehabilitation capacity. The stock is currently trading near the lower end of its 52-week range, with an average analyst target of $148.17.
Encompass Health Sets Q3 2026 Earnings Call Date. Encompass Health announced the date for its 2026 third-quarter earnings call. Recent coverage also highlights the company's small-format expansion strategy and potential undervaluation as it builds out its rehabilitation capacity. The stock is currently trading near the lower end of its 52-week range, with an average analyst target of $148.17.